Display options
Cite
Tu C, Gao D, Li XF, et al. Inflammatory stress potentiates emodin-induced liver injury in rats. Front Pharmacol. 2015;6:233doi: 10.3389/fphar.2015.00233.
Tu, C., Gao, D., Li, X. F., Li, C. Y., Li, R. S., Zhao, Y. L., Li, N., Jia, G. L., Pang, J. Y., Cui, H. R., Ma, Z. J., Xiao, X. H., & Wang, J. B. (2015). Inflammatory stress potentiates emodin-induced liver injury in rats. Frontiers in pharmacology, 6233. https://doi.org/10.3389/fphar.2015.00233
Tu, Can, et al. "Inflammatory stress potentiates emodin-induced liver injury in rats." Frontiers in pharmacology vol. 6 (2015): 233. doi: https://doi.org/10.3389/fphar.2015.00233
Tu C, Gao D, Li XF, Li CY, Li RS, Zhao YL, Li N, Jia GL, Pang JY, Cui HR, Ma ZJ, Xiao XH, Wang JB. Inflammatory stress potentiates emodin-induced liver injury in rats. Front Pharmacol. 2015 Oct 23;6:233. doi: 10.3389/fphar.2015.00233. eCollection 2015. PMID: 26557087; PMCID: PMC4615941.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2015 Oct 23;6:233. doi: 10.3389/fphar.2015.00233. eCollection 2015.

Inflammatory stress potentiates emodin-induced liver injury in rats.

Frontiers in pharmacology

Can Tu, Dan Gao, Xiao-Fei Li, Chun-Yu Li, Rui-Sheng Li, Yan-Ling Zhao, Na Li, Ge-Liu-Chang Jia, Jing-Yao Pang, He-Rong Cui, Zhi-Jie Ma, Xiao-He Xiao, Jia-Bo Wang

Affiliations

  1. China Military Institute of Chinese Medicine, 302 Military Hospital , Beijing, China.
  2. China Military Institute of Chinese Medicine, 302 Military Hospital , Beijing, China ; Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences , Beijing, China.
  3. China Military Institute of Chinese Medicine, 302 Military Hospital , Beijing, China ; School of Pharmacy, Shandong University of Traditional Chinese Medicine , Jinan, China.
  4. China Military Institute of Chinese Medicine, 302 Military Hospital , Beijing, China ; School of Pharmacy, Chengdu University of Traditional Chinese Medicine , Chengdu, China.
  5. China Military Institute of Chinese Medicine, 302 Military Hospital , Beijing, China ; Department of Traditional Chinese Medicine, Beijing Friendship Hospital of Capital Medical University , Beijing, China.
  6. Department of Traditional Chinese Medicine, Beijing Friendship Hospital of Capital Medical University , Beijing, China.

PMID: 26557087 PMCID: PMC4615941 DOI: 10.3389/fphar.2015.00233

Abstract

Herbal medicines containing emodin, widely used for the treatment of hepatitis in clinic, have been reported with hepatotoxicity in individuals. A modest inflammatory stress potentiating liver injury has been linked to the idiosyncratic drug-induced liver injury (IDILI). In this study, we investigated the hypothesis that lipopolysaccharide (LPS) interacts with emodin could synergize to cause liver injury in rats. Emodin (ranging from 20, 40, to 80 mg/kg), which is in the range of liver protection, was administered to rats, before LPS (2.8 mg/kg) or saline vehicle treatment. The biochemical tests showed that non-toxic dosage of LPS coupled with emodin caused significant increases of plasma ALT and AST activities as compared to emodin alone treated groups (P < 0.05). In addition, with LPS or emodin alone could not induce any changes in ALT and AST activity, as compared with the control group (0.5% CMC-Na treatment). Meanwhile, the plasma proinflammatory cytokines, TNF-α, IL-1β, and IL-6 increased significantly in the emodin/LPS groups compared to either emodin groups or the LPS (P < 0.05). Histological analysis showed that liver damage was only found in emodin/LPS cotreatmented rat livers samples. These results indicate that non-toxic dosage of LPS potentiates the hepatotoxicity of emodin. This discovery raises the possibility that emodin and herbal medicines containing it may induce liver injury in the inflammatory stress even in their therapeutic dosages.

Keywords: emodin; hepatotoxicity; idiosyncratic drug-induced liver injury; lipopolysaccharide; proinflammatory mediators; therapeutic dosages

References

  1. Eur J Pharmacol. 2008 Apr 14;584(1):175-84 - PubMed
  2. J Hepatol. 2013 Oct;59(4):842-58 - PubMed
  3. Chem Biol Interact. 2004 Nov 1;150(1):35-51 - PubMed
  4. J Hepatol. 2005 Nov;43(5):901-10 - PubMed
  5. Exp Toxicol Pathol. 2010 Nov;62(6):627-35 - PubMed
  6. World J Gastroenterol. 2009 Oct 14;15(38):4753-62 - PubMed
  7. Hepatology. 2001 Jan;33(1):66-73 - PubMed
  8. J Ethnopharmacol. 2011 Oct 11;137(3):1492-7 - PubMed
  9. J Gastroenterol Hepatol. 2009 Jun;24(6):943-54 - PubMed
  10. PLoS One. 2011;6(9):e24498 - PubMed
  11. Eur J Pharmacol. 2007 Dec 8;576(1-3):136-42 - PubMed
  12. Chin Med J (Engl). 2008 Jun 5;121(11):1010-4 - PubMed
  13. Mayo Clin Proc. 2001 Jul;76(7):688-94 - PubMed
  14. J Ethnopharmacol. 2015 Mar 13;162:61-8 - PubMed
  15. Yakugaku Zasshi. 2000 Oct;120(10):849-62 - PubMed
  16. J Ethnopharmacol. 2009 Jul 6;124(1):18-25 - PubMed
  17. J Pharmacol Exp Ther. 2006 Mar;316(3):1080-7 - PubMed
  18. J Hazard Mater. 2013 Feb 15;246-247:1-9 - PubMed
  19. Crit Rev Toxicol. 2011 Oct;41(9):723-39 - PubMed
  20. J Leukoc Biol. 2012 Jun;91(6):967-76 - PubMed
  21. Pharmacol Rev. 2009 Sep;61(3):262-82 - PubMed
  22. Biochem J. 2009 Jul 15;421(3):473-82 - PubMed
  23. Am J Med. 2004 Apr 1;116(7):478-85 - PubMed
  24. Basic Clin Pharmacol Toxicol. 2009 Jun;104(6):463-9 - PubMed
  25. J Pediatr Gastroenterol Nutr. 2005 Aug;41(2):256-8 - PubMed
  26. Toxicol Appl Pharmacol. 2013 Feb 1;266(3):430-8 - PubMed
  27. J Chromatogr A. 2013 Jul 5;1297:168-78 - PubMed
  28. Fibrogenesis Tissue Repair. 2010 Oct 21;3:21 - PubMed
  29. Cancer Res. 2013 Aug 15;73(16):4992-5002 - PubMed

Publication Types